Skip to main content

Tramadol and O-demethyltramadol disposition in humans: a pooled study

Introduction

To study the use of size, maturation and CYP2D6 genotype score as predictors of i.v. tramadol (M) disposition throughout human life, published observations were pooled [16].

Methods

M and O-demethyltramadol (M1) observations in 295 subjects (25 weeks postmenstrual age to 84.8 years) were available for population PK analysis (NON-MEM, two-compartment model for M and two additional compartments for M1). Covariates were weight, age, sex, disease (healthy/patient) and CYP2D6 genotype score. A sigmoid maturation model was used to describe changes in M (CLPO + CLPM), M1 formation (CLPM) and M1 elimination (CLMO) clearance. Phenotype-based and genotype-based models were used to distinguish poor CLPM subjects.

Results

Differences in M disposition between children and adults were largely accounted for by maturation and size. CKLPM (TM50 40.3 weeks, Hill 9.09) and CLPO (TM50 39.1 weeks, Hill 5.8) display fast maturation, while CLMO matures slower. The phenotype-based mixture model estimated that 8.6 were slow metabolizers (18.3% of normal CLPM). Genotype-based estimates were also lower (68%) but not all subjects with a low CYP2D6 score were in the poor metabolizer group.

Conclusions

Maturation of M elimination occurs early with 50% of adult values at full-term age. Maturation and age are key predictors, while CYP2D6 genotype score only explains some of the variability in M disposition.

References

  1. 1.

    Allegaert K, et al.: Br J Anaesth. 2008, 100: 525-532. 10.1093/bja/aen019

    CAS  Article  PubMed  Google Scholar 

  2. 2.

    Bressolle F, et al.: Br J Anaesth. 2009, 102: 390-399. 10.1093/bja/aen405

    CAS  Article  PubMed  Google Scholar 

  3. 3.

    Garrido MJ, et al.: Pharm Res. 2006, 23: 2014-2023. 10.1007/s11095-006-9049-7

    CAS  Article  PubMed  Google Scholar 

  4. 4.

    Lintz W, et al.: Int J Clin Pharmacol Ther. 1999, 37: 175-183.

    CAS  PubMed  Google Scholar 

  5. 5.

    Murthy BV, et al.: Br J Anaesth. 2000, 84: 346-349.

    CAS  Article  PubMed  Google Scholar 

  6. 6.

    Stamer UM, et al.: Clin Pharmacol Ther. 2007, 82: 41-47. 10.1038/sj.clpt.6100152

    CAS  Article  PubMed  Google Scholar 

Download references

Author information

Affiliations

Authors

Corresponding author

Correspondence to K Allegaert.

Rights and permissions

This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and Permissions

About this article

Cite this article

Allegaert, K., Stamer, U., Anderson, B. et al. Tramadol and O-demethyltramadol disposition in humans: a pooled study. Crit Care 15, P347 (2011). https://doi.org/10.1186/cc9767

Download citation

Keywords

  • Tramadol
  • Poor Metabolizer
  • Pool Study
  • Slow Metabolizers
  • Metabolizer Group